Drug Profile
NU 172
Alternative Names: NU172Latest Information Update: 05 Oct 2012
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer ARCA biopharma Inc
- Class Anticoagulants; Antithrombotics; Nucleotide aptamers
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 04 Oct 2012 Discontinued - Phase-I for Thrombosis in USA (IV)
- 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
- 04 Jun 2008 Nuvelo initiates enrolment in a phase Ib trial for Thrombosis in USA